Trending...
- TEÓNA Releases New Single "What I Want" — A Bold Anthem for Every Woman Who Once Had a Bad Love
- The CRE Finance Council Announces New Chairs for Industry Forums
- MetaSwap Exchange Rolls Out Multilingual Access System to Enhance Global User Experience
DUBLIN, May 13, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City at NASDAQ Tuesday, May 20 at 10:30 AM EDT (7:30 AM PDT / 3:30 PM IST) and will be hosting in-person meetings with the investment community at the conference.
A webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. A replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
More on Nyenta.com
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
[email protected]
650-808-4045
SOURCE Theravance Biopharma, Inc.
A webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. A replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
More on Nyenta.com
- PUSHERMAN- – Best Feature Documentary Official Winner at NYC and London Festivals
- Female Motorsports Sponsorship & Expansion; Acquisition Agreement of UAE-Based Sports Incubator by Online Lottery & Sports Game Provider: Lottery.com
- SupplyHouse Named One of Fortune's Best Workplaces in New York in 2025
- Kosinima, Inc. Unveils Third Cohort Of Grantees, Expanding Global Footprint For Black Filmmakers
- Global Court Momentum Builds Against Forced Psychiatry; CCHR Urges U.S. Reform
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
[email protected]
650-808-4045
SOURCE Theravance Biopharma, Inc.
Filed Under: Business
0 Comments
Latest on Nyenta.com
- Token-Operated Sake Service Opens at Tobu Nikko Station
- Kola Ewousho's new book, "Behind Enemy Lines," inspires strong Christian faith
- INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vestis
- The Italian Band Revue Opens The Firenze Rocks Festival
- Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
- From the Cradle of Civilization to the Vanguard of Tomorrow:
- DivX Enhances AVI Playback Resources; Simplifies Guide to Playing AVI Files with DivX Software
- Ton-Up Records Announces New Campaign Featuring Playlist Series, "Press Play"
- Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake
- Zywave Announces 2025 Cyber Risk Award Winners
- Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures
- PHOTOS: New York Road Runners Hosts Special Screening of "Final Finishers" Documentary Short Film During 2025 Tribeca Festival
- W. P. Carey Increases Quarterly Dividend to $0.900 per Share
- Rochester: Summer recreation schedules, programs to kickoff June 30 with all City pools for first time in five years
- McDonagh Family Office Deploys Advanced AI Platform to Supercharge Portfolio Company Growth
- Goldstar Rehabilitation Celebrates 15 Years of Early Intervention Across Southeastern PA
- United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
- D8Averse Launches D8Acapture: Disruptive Mobile-First App Transforms Utility Pole Data Collection
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
- "Keeping Her Dream Alive" – A Free Virtual Celebration of Blood Cancer Survivors - June 25, 2025